Enrollment completion of the BAGUERA® L study

Spineart is delighted to announce that 73 patients have been included, thus completing the enrollment of the BAGUERA® L study!

BAGUERA® L is a prosthesis intended as a replacement for a lumbar intervertebral disc, in patients with symptomatic lumbar disc disease. The patients were treated with BAGUERA® L from 2013 to 2018 in France and Germany. This study is monitoring the long-term safety and performance of BAGUERA® L.

We look forward to the results of this study and would like to thank Dr. Pedram from the Centre Aquitain du dos (France), Dr. Janata from the Grenzland MVZ (Germany), as well as their clinical teams, for their involvement and dedication to this clinical study and for reaching this milestone!

 Here are a few words from them on the BAGUERA® L:

“BAGUERA® L is a reliable implant for total disc replacement with very good long-term results. The instruments are user friendly and allow exact placement of the implant at the disc space.” commented Dr. Janata.

“BAGUERA® L combines ease of installation, MRI compatibility and the ability to choose a mobile or fixed core according to anatomical conditions.” said Dr. Pedram.

Related

Related items
Date - Category Illustration Title Excerpt
  • Corporate
26 September 2025 Plan-Les-Ouates & Zurich (CH) – Antwerp (BE) Spineart (www.spineart.com), a global medtech innovator in advanced spine surgery solutions, today announces a CHF 25 million capital increase backed...
  • Product
Spineart announces the full-market launch of its SCARLET® AC-Ti secured anterior cervical cage in the United States. Following 510(k) clearance in May 2024, SCARLET® AC-Ti has been extensively evaluated by...
  • BAGUERA® C
Spineart today announces that it has completed a planned interim analysis for its 2-level BAGUERA® C IDE study, which showed that BAGUERA® C, its innovative cervical disc prosthesis, met the...